Company Profile
NeuroSense Therapeutics Stock Price, News & Analysis
- Ticker:
- NRSN
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, NeuroSense Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
0.77 USD (-2.69%)
Close
Last updated: June 23, 2026 at 00:00
27.72M USD
Market cap
Why the stock is moving
NRSN is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
NeuroSense Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, NeuroSense Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
NeuroSense Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, NeuroSense Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
Source: NeuroSense Therapeutics
- 02
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
Source: NeuroSense Therapeutics
- 03
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
Source: NeuroSense Therapeutics
- 04
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
Source: NeuroSense Therapeutics
- 05
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
Source: NeuroSense Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of NeuroSense Therapeutics (NRSN)?
NeuroSense Therapeutics (NRSN) most recently closed at 0.77 USD, a -2.69% move versus the previous session.
What is the market cap of NeuroSense Therapeutics (NRSN)?
NeuroSense Therapeutics currently has a market capitalization of 27.72M USD on BioPharmSignal.
What does NeuroSense Therapeutics do?
NeuroSense Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is NRSN stock listed?
NeuroSense Therapeutics (NRSN) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, NeuroSense Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is NeuroSense?
NeuroSense Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is NeuroSense Therapeutics targeting with NeuroSense?
NeuroSense Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
NeuroSense Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.